Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “buy” rating reiterated by research analysts at Cowen in a research report issued on Friday.
A number of other analysts have also weighed in on the stock. Wedbush increased their target price on shares of Audentes Therapeutics to $56.00 and gave the stock an “outperform” rating in a report on Thursday, January 4th. BidaskClub lowered shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Zacks Investment Research lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 17th. Leerink Swann reiterated an “outperform” rating and set a $29.00 target price (up from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Finally, HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $35.56.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $36.24 on Friday. The firm has a market cap of $1,255.59, a PE ratio of -10.66 and a beta of 0.89. Audentes Therapeutics has a 1-year low of $13.90 and a 1-year high of $41.80.
In other Audentes Therapeutics news, major shareholder Orbimed Advisors Llc sold 433,210 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $35.11, for a total value of $15,210,003.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The disclosure for this sale can be found here. Insiders sold 872,848 shares of company stock valued at $30,594,852 over the last 90 days. 47.30% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in Audentes Therapeutics in the third quarter worth about $143,000. Teacher Retirement System of Texas purchased a new stake in Audentes Therapeutics in the fourth quarter worth about $208,000. MetLife Investment Advisors LLC bought a new position in shares of Audentes Therapeutics during the fourth quarter valued at approximately $248,000. Nationwide Fund Advisors increased its stake in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in shares of Audentes Therapeutics during the third quarter valued at approximately $295,000. Institutional investors and hedge funds own 67.35% of the company’s stock.
WARNING: “Audentes Therapeutics’ (BOLD) “Buy” Rating Reaffirmed at Cowen” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3254695/audentes-therapeutics-bold-buy-rating-reaffirmed-at-cowen.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.